Last updated on April 2017

Hodgkin Lymphoma Molecular Profiling and Clinical Outcomes in U.S. Community Oncology Practices


Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions: Lymphoma
  • Age: 18 Years
  • Gender: Male or Female

Inclusion Criteria

  1. Men and women ≥18 years of age
  2. Histologically confirmed diagnosis of Classical Hodgkin Lymphoma (cHL)
  3. Patients who are treatment-naïve or are within ± 2 weeks of Day 1 of Cycle 1 of any line of therapy at time of enrollment
  4. Patients must be within ± 2 weeks of Day 1 of the first cycle of any line of therapy to enroll; a cycle is practice-defined for chemotherapy, targeted therapy, or immunotherapy based regimens.
  5. Patients enrolled, who receive anti-cancer therapy, and who go on to receive only supportive, palliative, hospice, or end-of-life care remain on study and should not be discontinued from follow-up.
  6. Any Eastern Cooperative Oncology Group (ECOG) or Karnofsky performance status (PS)
  7. Patients must have available medical records for the date of diagnosis of cHL.
  8. Patients must have available medical records documenting any prior treatment and treatment dates for the Hodgkin lymphoma, including chemotherapy, radiation, surgery and other anticancer therapy received.
  9. Patients must consent to use their FPFE tissue blocks, blood or serum samples, for exploratory analyses
Exclusion Criteria
  1. Patients with unknown date of diagnosis of cHL
  2. Patients whose prior therapy and dates of therapy (eg, surgery, radiation, or drug therapy) are unknown
  3. Any other (non-HL) active malignancy for which the patient is receiving treatment
  4. Patients participating in a clinical study that does not allow enrollment into a noninterventional study
  5. At time of enrollment, patients who are receiving supportive, palliative, hospice or end-of life care only and not receiving anti-cancer therapy will be excluded.
  6. Patients enrolled who receive anti-cancer therapy, and who go on to receive only supportive, palliative, hospice, or end-of-life care remain on study and should not be discontinued from follow-up.

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.